Register to take part in a study today

Glasgow Memory Clinic is attending the Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD) in Torino

Glasgow Memory Clinic attends a range of networking events every year because they contribute to their knowledge of up and coming clinical studies. These events are held all over the world with the next one, Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD), being held from the 15 to 18 March in Torino, Italy.

This year’s AAT-AD/PD Focus Meeting is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and AD/PD. This Alzheimer’s disease conference and Parkinson’s disease conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.

A key focus of the conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers discussed in the sessions and corridors at AD/PD 2017. The aim is to drive successful collaborations among academia and industry, leading to the development of innovative drugs and ultimately providing a better and brighter future for patients and families affected by neurodegenerative diseases.

The conference will cover topics such as:


  • The placebo effect in AD and PD
  • The puzzle of treating Alzheimer’s in traditional settings
  • Trials, tribulations, progress and new developments in Tau Imaging
  • Alzheimer patients and somatic diseases: hospital vs home treatment
  • Future directions in the treatment of Parkinson’s disease
  • Time trends in the incidence of Dementia and Parkinsonism


Speakers include Fabrizio Benedetti, from the University of Turin, Kaj Blennow from the University of Gothenburg, Samantha Budd-Haeberlain from Biogen, Claudio Cuello from McGill University in Canada and Monica Di Luca from the University of Milano.

Events like these are hugely important as they offer a collaborative opportunity to accelerate clinical development and improve trial quality by benchmarking and enhancing clinical practices and partnering.

Posted 7th March 2018

Leave a Reply